|
Wednesday, March 10th, 2010 |
|
News
Below are recent news items and publications relating to The Bruckner Group.
| Recent News |
| 12-2008 |
-
Article in The Pink Sheet highlights The Bruckner Group's industry leadership on healthcare value issues and strategy
An article published in the December 1, 2008 edition of The Pink Sheet highlights The Bruckner Group's industry leadership in healthcare value issues and strategy. The article, entitled "New Drugs for Rare Diseases Face Higher Reimbursement Hurdles," extensively quotes Bruckner partner David Balekdjian. The article discusses how payers are now scrutinizing new cancer, HIV, and rare disease treatments for their healthcare value. This is a significant change from previous practices, in which these diseases were largely exempted from this scrutinization. Further, the article highlights the industry-leading approach that Bruckner has developed, which effectively and cost-efficiently helps companies develop and maximize the healthcare value of their therapeutics. See the press release of even date (below) for more information.
|
| 11-2008 |
-
National Organization For Rare Disorders (NORD) invites Bruckner partner David Balekdjian to speak to NORD's Corporate Council
The Bruckner Group and the National Organization for Rare Disorders (NORD) announce that NORD has invited Bruckner partner David Balekdjian to present a speech to NORD's semi-annual Corporate Council meeting in Washington D.C. on November 18, 2008. David Balekdjian's speech will be entitled "The Intensifying Payer Climate Facing New Rare Disease Therapies, and What Manufacturers Need To Do About It." See the press release of even date for more details.
|
| 11-2008 |
-
American Association of Pharmaceutical Scientists (AAPS) invites Bruckner partner David Balekdjian to speak at its annual national meeting on: "The Exubera Case: What Lessons Does It Hold For Future Drug Developments"
The American Association of Pharmaceutical Scientists (AAPS) invited Bruckner partner David Balekdjian to make a speech at its annual conference in Atlanta. David's speech is entitled "The Exubera Case: What Lessons Does It Hold For Future Drug Developments?"
In his speech, David Balekdjian presents a case study of Exubera's failure (which The Bruckner Group predicted in a very high profile article published in Business Week at the time of Exubera's launch in February 2006). Further, the speech summarizes the lessons that Exubera's failure make clear and which should guide new drug developments. And finally, the speech presents a specific framework for how pharma and biotech companies need to develop new drugs so that payers' healthcare value and other needs are addressed (alongside the needs of the FDA, physicians, and patients), so that at launch, the drug will have a differentiating and compelling healthcare value proposition that fully aligns with the market.
|
| 05-2008 |
-
2008 PCMA Specialty Pharmacy Symposium to Feature Speech by David Balekdjian
The Bruckner Group is pleased to announce that David Balekdjian, a principle of the firm, will be speaking at the 2008 PCMA Specialty Pharmacy Symposium in Chicago on May 6, 2008. See the press release issued by The Bruckner Group for more details.
|
| 02-2008 |
-
Nature Biotechnology article by two Bruckner Group partners provides advice on addressing the new risks pharma and biotech companies face from payers' focus on the healthcare value of biologicals
The Bruckner Group is pleased to announce the publication in Nature Biotechnology of "Weighing the Outcomes," the expansive feature article in the February 2008 issue written by Bruckner Group partners Michael Russo and David Balekdjian. The article, a white paper and snapshot from a forthcoming book, explores how the intensification of managed care and employer focus on biological drugs' healthcare value, and payer influence over patient access to biological drugs, is presenting new risks for pharma and biotech companies. The article presents advice and actionable recommendations to companies and executives. Please see the press release (below) of February 13, 2008, for more information.
|
| 11-2007 |
-
CardioVascular BioTherapeutics engages The Bruckner Group to find a joint commercialization partner
Please see the press release dated 11/27/07.
|
| 11-2007 |
-
Phage Biotechnology Corp. engages The Bruckner Group to find a joint commercialization partner for its portfolio of innovative recombinant proteins, standard of care therapies, development platforms, and technologies.
See the press release of even date for more information.
|
| 10-2007 |
-
The failure of Pfizer's Exubera predicted in a Business Week article written by BGI partners Russo and Balekdjian in February 2006
Pfizer's October 17, 2007 announcement that it was taking a $2.8 billion charge against earnings and discontinuing Exubera, its inhaled insulin therapy, was predicted in Business Week in an article written by Bruckner Group partners Michael Russo and David Balekdjian and published on February 15, 2006. See the attached press release (below), which provides a top-level post-mortem and includes an electronic link to the article.
|
| 07-2007 |
-
BusinessWeek article highlights Bruckner Group study
BusinessWeek published an article on July 6 discussing the race by pharmaceutical and biotechnology companies to be first to bring to market an effective angiogenesis treatment for cardiovascular disease. The article cites a Bruckner Group study for CardioVascular BioTherapeutics presenting the preliminary value propostion for CVBT's angiogenic therapy FGF-1. For more information and a direct link to the article, please see the Press Releases section.
|
| 06-2006 |
-
Inadequate Response to Managed Markets Challenges Poses High Revenue Risk for Pharma and Biotech Companies, According to Business Week Article by Two Bruckner Group Partners
Business Week has published an article by two Bruckner Group partners in the Outside Shot column in the June 19, 2006 issue, entitled "Drugmakers: A Dose of Reality." The article describes how many pharma and biotech companies have failed to evolve, simply not incorporating solid valid propositions at a pace and level commensurate to the health insurance industry’s incremental rollout of cost-conscious drug management efforts. As a result, emergent managed markets strategies have throttled many drug manufacturers’ business models. The article further explains why BGI’s approach to solving this problem, outcomes-based access (OBA), can help drugmakers meet the challenges of the managed markets channel, overcome access restrictions, and prove the value of their drugs. See the press release of June 14, 2006, for more information.
|
| 02-2006 |
-
Business Week Article by BGI Partners Indicates Exubera Market Performance Likely to Disappoint Pfizer Stakeholders.
In an article published in Business Week, Bruckner Group Partners Michael J. Russo and David Balekdjian apply an outcomes-based access (OBA) analysis to Pfizer's Exubera, with the conclusion that Exubera's market performance is likely to disappoint Pfizer stakeholders because Exubera offers an unacceptable value proposition to payers. Exubera is used in this article as a case study for the type of OBA analysis that should be conducted to prepare for new product launches, in order to maximize market acceptance, uptake, and success. See the press release of February 15, 2006, for more information.
|
| 11-2005 |
-
Hepatitis C Leadership Summit (HCVLS) Explores Opportunities For Elevating the Response to the HCV Epidemic.
The first annual Hepatitis C Leadership Summit (HCVLS), held October 28-30, 2005 in Boston, brought together 75 HCV stakeholder leaders to explore opportunities to elevate the response to the HCV epidemic using currently-available resources. The HCVLS was developed and organized by the Healthcare Advocacy and Research Collaboration Project, a non-profit organization, and The Bruckner Group. Further information can be found in the 11/30/2005 press release posted on this site.
|
| Press Releases |
| 12-2008 |
-
Pink Sheet article highlights The Bruckner Group's industry leadership in healthcare value issues and strategy
An article published in the December 1, 2008 edition of The Pink Sheet highlights The Bruckner Group's industry leadership in healthcare value issues and strategy. The article, entitled "New Drugs for Rare Diseases Face Higher Reimbursement Hurdles," extensively quotes Bruckner partner David Balekdjian. Further, the article highlights the industry-leading approach that Bruckner has developed, which effectively and cost-efficiently helps companies develop and maximize the healthcare value of their therapeutics.
|
|
| 11-2008 |
-
National Organization for Rare Disorders (NORD) invites Bruckner Group partner David Balekdjian to present a speech at NORD's Corporate Council Meeting
The Bruckner Group and The National Organization for Rare Disorders (NORD) are pleased to announce that NORD has invited Bruckner partner David Balekdjian to present a speech at NORD's semi-annual Corporate Council meeting on November 18, 2008. The speech is entitled "The Intensifying Payer Climate Facing New Rare Disease Therapies, and What Manufacturers Developing New Therapies Need To Do About It."
|
|
| 05-2008 |
-
PCMA Specialty Pharmacy Symposium To Feature Speech By David Balekdjian
The Bruckner Group is pleased to announce that David Balekdjian will be speaking at the 2008 PCMA Specialty Pharmacy Symposium in Chicago on May 6, 2008. David will discuss how managed care and PBM demands for healthcare value have and continue to transform the pharma and biotech industries.
|
|
| 02-2008 |
-
Nature Biotechnology publishes feature article by two Bruckner Group partners
The Bruckner Group is pleased to announce the publication in Nature Biotechnology of an expansive feature article in the February 2008 issue, "Weighing The Outcomes," written by Bruckner Group partners Michael Russo and David Balekdjian.
|
|
| 11-2007 |
-
CardioVascular BioTherapeutics Engages The Bruckner Group to Find a Joint Commercialization Partner
CardioVascular BioTherapeutics Inc. (CVBT) has engaged The Bruckner Group (BGI) to find a joint commercialization partner for CVBT-141H, a highly promising protein therapy for treating advanced coronary artery disease patients.
|
|
| 11-2007 |
-
Phage Biotechnology Corp. Engages The Bruckner Group to Find Joint Commercialization Partner
Phage Biotechnology Corp. (www.phagebiotech.com) has engaged The Bruckner Group to find a joint commercialization partner for its portfolio of innovative recombinant protein treatments, standard of care therapies, development platforms, and technologies.
|
|
| 10-2007 |
-
The Failure of Pfizer's Exubera Predicted in BusinessWeek by The Bruckner Group in February 2006
Pfizer's October 17, 2007 announcement that it was taking a $2.8 billion charge against earnings and discontinuing Exubera, its inhaled insulin therapy, was predicted in Business Week in an article written by Bruckner Group partners Michael Russo and David Balekdjian and published on February 15, 2006. The attached press release provides a top-level post-mortem and includes an electronic link to the article.
|
|
| 07-2007 |
-
BusinessWeek article highlights Bruckner Group study
BusinessWeek published an article on July 6 discussing the race by pharmaceutical and biotechnology companies to be first to bring to market an effective angiogenesis treatment for cardiovascular disease. The article highlights CardioVascular BioTherapeutic's FGF-1, which is showing potential breakthrough patient outcomes for treating advanced coronary artery disease patients.
|
|
| 06-2006 |
-
Business Week Publishes Article by Two Bruckner Group Partners in June 19, 2006 Issue
The Bruckner Group is pleased to announce that Business Week magazine has published a second article by two Bruckner Group partners, David Balekdjian and Michael J. Russo. The article, entitled "Drugmakers: A Dose of Reality," appears in the Outside Shot column in the June 19, 2006 issue. The article describes how many pharma and biotech companies have failed to evolve at a pace and level commensurate to the health insurance industry’s incremental rollout of cost-conscious drug management efforts. The lack of a proactive commensurate response to these challenges poses a high revenue risk to manufacturers, due to the outcomes-based restrictions payers are implementing. It further explains why BGI’s approach to solving this problem, outcomes-based access (OBA), can help drugmakers meet the challenges of the managed markets channel, overcome access restrictions, and prove the value of their drugs.
|
|
| 02-2006 |
-
Article in Busines Week by Bruckner Group Partners Predicts that Exubera's Market Performance Will Disappoint Pfizer Stakeholders
In an article published on February 15, 2006 in Business Week, BGI partners Michael J. Russo and David Balekdjian predict that Exubera, the first inhaled insulin therapy from Pfizer, will experience market performance that will disappoint Pfizer stakeholders. Applying a rigorous OBA analysis to Exubera as a case study, the authors demonstrate that Exubera's insufficient value proposition to payers will likely lead to significant utilization restrictions that will dramatically impact Exubera revenues.
|
|
| 11-2005 |
-
First Annual Hepatitis C (HCV) Leadership Summit Engages HCV Stakeholders to Elevate the Response to the HCV Epidemic
Summary of the program at the first annual Hepatitis C Leadership Summit (HCVLS) October 28-30, 2005, developed by the Healthcare Advocacy and Research Collaboration Project (HARCP) and The Bruckner Group (BGI).
|
|
| 11-2005 |
-
Rare Disease Disorder Patients Facing Access Restrictions on Specialty Pharmaceuticals
In a speech presented at the Annual Meeting of the National Organization of Rare Diseases (NORD) in October 2005, Bruckner Group Partner Michael J. Russo warned that rare disease disorder patients are facing new access restrictions on specialty pharmaceuticals.
|
|
| 10-2005 |
-
Hepatitis C Leadership Summit, October 29-30, Seeks to Elevate the Current Response to the Hepatitis C Epidemic
The Healthcare Advocacy and Research Collaboration Project (HARCP) and The Bruckner Group announce the Hepatitis C Leadership Summit (HCVLS), October 29-30 2005, in Boston. The HCVLS is seeking to elevate the response to the hepatitis C epidemic, and to specifically explore opportunities to increase the number of patients tested and treated for hepatitis C with currently available resources.
|
|
| 01-2005 |
-
Biotechnology Drug Revenues Will Be Hard Hit By Strict Benefit and Coverage Restrictions
The Bruckner Group announces select findings from the fourth annual Bruckner Group Payor Study. The 2005 study details how biologicals, which have received minimal pharmacoeconomic scrutiny from payors, increasingly will face the same strict value-based review and administration processes of pharmaceuticals. Many of the highest-cost chronic therapies will be even more rigorously managed and challenged.
|
|
| 09-2004 |
-
New Training Programs for Marketing, Pharmacoeconomic, and Sales Challenges of Pharma and Biotech Companies
The American Management Association (AMA) and The Bruckner Group (BGI) announce new training programs that address major marketing, pharmacoeconomic, and sales challenges facing pharmaceutical and biotechnology manufacturers.
|
|
| 05-2004 |
-
U.S. Army/Bruckner Group Hepatitis C Study Results Announced
Released on May 18, 2004
|
|
| 09-2003 |
-
PMC Plenary Panel Announcement
The Pharmaceutical Marketing Congress announces the 2003 plenary panel. The program, developed by The Bruckner Group, features a panel consisting of Senator Arlen Specter (R-PA); Mr. Cedric Philipp, former senior executive at Wyeth Pharmaceuticals; and Dr. Robert Seidman, Chief Pharmacy Officer, WellPoint Health Networks. David Balekdjian, a Bruckner Group Partner, serves as program developer and panel moderator.
|
|
|
|
|
